57980-69-5

Basic information

• Product Name: 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-
• CAS NO: 57980-69-5
• Molecular Formula: C10H9NO4S
• Molecular Weight: 239.252
• Mol File: 57980-69-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-(57980-69-5)
• EPA Substance Registry System: 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-(57980-69-5)

Safety Data

• Hazardous Substances Data: 57980-69-5(Hazardous Substances Data)

Upstream product

• 64419-24-5 2,4-dihydroxybenzonitrile 
• 7048-04-6 L-cysteine hydrochloride monohydrate 
• 52-90-4 L-Cysteine 
• 52-89-1 l-cysteine hydrochloride 

Downstream Products

• 1393371-52-2 2-(2,4-dihydroxyphenyl)thiazol-4-carboxylic acid 

Relevant articles and documents

Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues

Additional structure-activity studies of desferrithiocin analogues are carried out. The effects of stereochemistry at C-4 on the ligands' iron clearing efficiency are reviewed and assessed using the enantiomers 4,5- dihydro-2-(2,4-dihydroxyphenyl)thiazole-4(R)-carboxylic acid and 4,5-dihydro- 2-(2,4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid. The utility of 4'- hydroxylation as a method of reducing the toxicity of desazadesferrithiocin analogues is also examined further with the synthesis and in vivo comparison of 4,5-dihydro-2-(2-hydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid, which is the natural product 4-methylaeruginoic acid, and 4,5-dihydro-2- (2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid. The stereochemistry at C-4 is shown to have a substantial effect on the iron clearing efficiency of desferrithiocin analogues, as does C-4'-hydroxylation on the toxicity profile. All of the compounds are evaluated in a bile-duct- cannulated rodent model to determine iron clearance efficiency and are carried forward to the iron-overloaded primate for iron clearing measurements. On the basis of the results of the present work, although 4,5- dihydro-2-(2,4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid is still the most promising candidate for clinical evaluation, 4,5-dihydro-2-(2,4- dihydroxyphenyl)4-methylthiazole-4(S)-carboxylic acid (4'- hydroxydesazadesferrithiocin) also merits further preclinical assessment.

NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.